Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The main objective is to assess the effect of lanreotide Autogel 120 mg administered every 28 days compared to placebo, on progression-free survival in patients with well or moderately differentiated non functioning entero-pancreatic endocrine tumour.
Critère d'inclusion
- Non functioning entero-pancreatic tumours